Skip to content

Liver and lung metastasis

TL;DR — Colorectal liver or lung metastases are not automatically incurable: selected patients achieve long survival after complete local treatment, but selection is the dominant confounder. Resectability means all disease can be cleared while preserving adequate organ function, not a fixed number or size threshold. For initially resectable liver metastases, perioperative FOLFOX improved progression-free survival but not overall survival in EORTC 40983 (Nordlinger 2013, PMID 24120480). Adding cetuximab to perioperative chemotherapy worsened long-term outcomes in New EPOC despite RAS-selected advanced-disease activity (Bridgewater 2020, PMID 32014119). Thermal ablation is most reliable for small lesions with adequate margins; lung metastasectomy lacks secure randomized benefit because PulMiCC was underpowered and control survival was far better than assumed (Milosevic 2020, PMID 32388895). Liver transplantation can yield 5-year survival >80% in highly selected unresectable liver-only disease, but disease-free survival is much lower and expanded criteria perform poorly (Dueland 2020, PMID 31188200; Smedman 2020, PMID 32333527).

Biology before technique

Domain Favorable signal Adverse signal
Distribution Liver- or lung-limited Multisite/peritoneal disease
Tempo Long disease-free interval, stable/responding Progression on active therapy
Burden Few/small lesions Numerous/bilobar or bulky lesions
Molecular RAS/BRAF WT, favorable response context BRAF V600E, resistant clones
Marker Low/falling CEA Very high/rising CEA
Local clearance Adequate future liver/remnant function and margins Inability to clear all meaningful disease

None is an absolute rule. A multidisciplinary team should integrate anatomy, biology, comorbidity and patient goal.

Defining resectability

Modern liver resectability asks whether all visible disease can be removed/ablated with adequate vascular inflow, outflow, biliary drainage and future liver remnant. It is not limited to four lesions or unilobar disease.

State Definition Next step
Resectable R0/R1-intent clearance feasible now Surgery-first or perioperative strategy
Borderline Feasible with hypertrophy, staged surgery or complex reconstruction Specialist hepatobiliary plan
Convertible Response could make complete clearance feasible Response-maximizing systemic therapy
Unresectable Clearance incompatible with organ function or disease distribution Systemic therapy ± trials/local palliation

Systematic review found conversion studies often failed to define unresectability; reported R0 rates ranged 22–57% in liver-specific trials and 11–38% in broader metastatic trials, making cross-study comparison unreliable (Bolhuis 2020, PMID 33189037).

Imaging and multidisciplinary review

Contrast CT stages chest/abdomen/pelvis. Liver MRI with hepatobiliary contrast improves small-lesion mapping after chemotherapy; PET/CT is selective for occult extrahepatic disease and transplant workup.

Imaging should be reviewed by the surgeons/interventionalists who may treat the disease. “Unresectable” from a report without specialist review is not a final biological state.

Resectable liver metastases

Surgery

Parenchymal-sparing hepatectomy preserves future options because recurrence is common. Major hepatectomy may be required for vascular/biliary anatomy but should not be used merely for wide margins.

Simultaneous versus staged colorectal and liver operations depend on primary symptoms, rectal neoadjuvant plan, liver complexity and institutional expertise.

Perioperative chemotherapy: EORTC 40983

EORTC 40983 randomized 364 patients with up to four resectable liver metastases to six cycles FOLFOX4 before and after surgery versus surgery alone. Three-year PFS improved by 7.3 percentage points in all randomized patients (HR 0.79, 95% CI 0.62–1.02) and 9.2 points among resected patients (Nordlinger 2008, PMID 18358928).

At median 8.5 years, OS did not differ significantly: HR 0.88 (95% CI 0.68–1.14); median OS 61.3 versus 54.3 months (Nordlinger 2013, PMID 24120480).

Interpretation Supported?
Perioperative FOLFOX improves PFS Yes
It proves an OS benefit No
Every resectable patient needs preoperative therapy No
Progression during therapy reveals adverse biology Clinically plausible, selected evidence

Reviews emphasize that perioperative treatment can test biology but also causes liver injury and can lose a surgical window (Beppu 2015, PMID 25713806; Padmanabhan 2015, PMID 25713808).

Systematic reviews of comparative neoadjuvant studies reach the same boundary: recurrence-risk selection may justify perioperative therapy, but the evidence does not support delaying straightforward resection merely to demonstrate response in every patient (Jones 2013, PMID 23726258; Nigri 2015, PMID 25257725).

New EPOC caution

New EPOC randomized chemotherapy with or without cetuximab in KRAS-wild-type resectable/suboptimally resectable liver metastases. Cetuximab shortened PFS and long-term OS, despite anti-EGFR benefit in unresectable left-sided disease (Bridgewater 2020, PMID 32014119).

This is a key boundary: activity in measurable metastatic disease does not prove perioperative eradication of micrometastases.

Conversion therapy

Conversion therapy should maximize response while scheduling repeat liver review before cumulative toxicity or resistant progression.

CAIRO5 centrally defined unresectability and re-reviewed imaging every 2 months. In right-sided or RAS/BRAF-mutant disease, FOLFOXIRI–bevacizumab improved PFS and local-treatment rate versus doublet–bevacizumab; in left-sided RAS/BRAF-WT disease, panitumumab increased response but did not simply translate into superior local treatment across all endpoints (Bond 2023, PMID 37329889).

Tumor context Common conversion approach
Left-sided RAS/BRAF WT, response priority Doublet + anti-EGFR
RAS/BRAF-mutant or right-sided, fit FOLFOXIRI + bevacizumab
Less fit Doublet + bevacizumab or individualized
dMMR/MSI-high Checkpoint therapy with early surgical reassessment

Consensus documents stress central resectability review, but definitions differ internationally (Torres 2016, PMID 27759781).

Techniques that expand resectability

Technique Purpose Principal risk
Portal-vein embolization Hypertrophy of future remnant Progression while waiting
Two-stage hepatectomy Clear bilobar disease sequentially Failure to reach stage two
ALPPS Rapid hypertrophy High morbidity; strict selection
Parenchymal-sparing combined resection/ablation Preserve liver volume Local recurrence if inadequate margin
Vascular reconstruction Clear vessel-involving disease Technical morbidity

Technical innovation should be judged by completion, morbidity, disease-free and overall survival—not resection rate alone.

Thermal ablation

Radiofrequency or microwave ablation is used for small lesions, poor surgical candidates, parenchymal preservation or recurrence. Outcomes worsen with larger tumors, heat-sink near vessels and small margins.

Comparative EORTC analyses reported local recurrence per lesion 5.5% after resection and 6.0% after RFA in selected ≤4-cm lesions; for RFA lesions ≤3 cm it was 2.9%, but groups differed in disease burden (Tanis 2014, PMID 24411080).

The evidence gap changed during this audit. A PubMed search updated through 2026-08-30 identified a 2026 meta-analysis incorporating one randomized trial and six propensity-matched or target-trial-emulation studies for metastases ≤3 cm. Thermal ablation was not associated with a statistically significant difference in OS (HR 0.92, 95% CI 0.79–1.07) or DFS/PFS (HR 1.01, 95% CI 0.90–1.14), and had fewer overall complications (RR 0.38, 95% CI 0.28–0.52); one randomized trial plus nonrandomized evidence does not establish universal interchangeability, so anatomy and expertise still govern selection (Su 2026, PMID 42463528).

Recurrence after liver treatment

Recurrence is common and does not automatically preclude further curative-intent therapy. Repeat resection, ablation or stereotactic radiation can be considered when all active disease remains controllable.

Immune response in resected metastases and clinicopathologic scores are prognostic, but no score should automatically deny a technically sound strategy (Tanis 2015, PMID 26342674; Sorbye 2012, PMID 22314329).

An individual-patient meta-analysis of systemic chemotherapy around resectable liver metastases reinforces modest disease-control benefit and uncertainty around OS (Bregni 2025, PMID 41197289).

Lung metastases

Pulmonary nodules require confirmation of metastatic probability, exclusion of a new lung primary and assessment of extrapulmonary disease.

Local options include wedge/segmental resection, stereotactic ablative radiotherapy and thermal ablation. Reported observational survival is profoundly selected by low burden and slow biology (Stewart 2018, PMID 30526930).

PulMiCC

PulMiCC attempted randomized metastasectomy versus active monitoring but stopped for poor recruitment. In 65 randomized patients, HR for death within 5 years was 0.82 (95% CI 0.43–1.56), unable to establish benefit (Treasure 2019, PMID 31831062).

Updated analysis of 93 randomized patients found median survival 3.5 years after metastasectomy and 3.8 years in controls; HR 0.93 (95% CI 0.56–1.56) (Milosevic 2020, PMID 32388895). The crucial finding is that control survival was not near zero.

Claim Evidence status
Selected patients live long after lung surgery Strong observational evidence
Surgery caused that survival Uncertain
Control patients die rapidly without surgery Refuted by PulMiCC
Ablation/SBRT is equivalent to surgery Unproven

Practice reviews explicitly describe the weak causal evidence behind pulmonary metastasectomy (Treasure 2014, PMID 24415715).

Liver transplantation

Transplant replaces the entire liver and removes otherwise unresectable liver-only disease at the cost of scarce grafts, immunosuppression and recurrent cancer.

SECA-I comparison reported 5-year OS 56% after transplant versus 9% in a nonrandomized chemotherapy cohort, despite similar DFS/PFS of 8–10 months (Dueland 2015, PMID 24950280). The comparison is highly selected and nonrandomized.

SECA-II applied stricter selection and reported 5-year OS 83%, with 3-year DFS 35%; recurrence was often slow-growing lung disease amenable to treatment (Dueland 2020, PMID 31188200).

In pooled prospective cohorts, 5-year OS was 100% for Fong score 0–2, 78% in the low metabolic-tumor-volume group and 67% for Oslo score 0–2, illustrating the magnitude of selection (Dueland 2020, PMID 31674105).

Expanded criteria performed poorly: SECA-II arm D had median DFS 4 months and OS 18 months (Smedman 2020, PMID 32333527). Transplant is therefore a protocolized selected intervention, not a substitute for unresectability.

Reviews emphasize graft allocation, living-donor ethics, recurrence and the need for randomized comparison (Line 2020, PMID 32305529; Maspero 2023, PMID 36672295).

Early transplant reviews correctly treated the approach as hypothesis-generating because impressive OS coexisted with near-universal recurrence and extreme selection (Simoneau 2019, PMID 30839338).

Open questions

  • Which resectable liver-metastasis patients gain OS from perioperative chemotherapy? (Nordlinger 2013, PMID 24120480)
  • Which anatomy, margin and expertise criteria identify patients for whom ablation and resection offer comparable long-term control after the first randomized comparison? (Su 2026, PMID 42463528)
  • Which molecular/response criteria best predict successful conversion? (Bond 2023, PMID 37329889)
  • Does lung metastasectomy benefit a biologically defined subgroup despite PulMiCC uncertainty? (Milosevic 2020, PMID 32388895)
  • Can transplant selection and graft policy produce survival benefit without unacceptable opportunity cost? (Dueland 2020, PMID 31188200)

References

  1. Nordlinger B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-15. PMID 24120480
  2. Bridgewater JA, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398-411. PMID 32014119
  3. Milosevic M, et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis. 2020;22(10):1314-1324. PMID 32388895
  4. Dueland S, et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Ann Surg. 2020;271(2):212-218. PMID 31188200
  5. Smedman TM, et al. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open. 2020;4(3):467-477. PMID 32333527
  6. Bolhuis K, et al. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. Eur J Cancer. 2020;141:225-238. PMID 33189037
  7. Nordlinger B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007-16. PMID 18358928
  8. Beppu T, et al. Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases. Hepatobiliary Surg Nutr. 2015;4(1):72-5. PMID 25713806
  9. Padmanabhan C, Parikh A. Perioperative chemotherapy for resectable colorectal hepatic metastases-What does the EORTC 40983 trial update mean? Hepatobiliary Surg Nutr. 2015;4(1):80-3. PMID 25713808
  10. Jones RP, et al. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol. 2013;39(8):807-11. PMID 23726258
  11. Nigri G, et al. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. Surgeon. 2015;13(2):83-90. PMID 25257725
  12. Bond MJG, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023;24(7):757-771. PMID 37329889
  13. Torres OJ, et al. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig. 2016;29(3):173-179. PMID 27759781
  14. Tanis E, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014;50(5):912-9. PMID 24411080
  15. Tanis E, et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer. 2015;51(17):2708-17. PMID 26342674
  16. Sorbye H, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012;255(3):534-9. PMID 22314329
  17. Bregni G, et al. Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis. Eur J Cancer. 2025;231:116092. PMID 41197289
  18. Stewart CL, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018;55(9):330-379. PMID 30526930
  19. Treasure T, et al. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20(1):718. PMID 31831062
  20. Treasure T, et al. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69(10):946-9. PMID 24415715
  21. Dueland S, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015;261(5):956-60. PMID 24950280
  22. Dueland S, et al. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2020;20(2):530-537. PMID 31674105
  23. Line PD, et al. Liver transplantation for colorectal liver metastases: What do we need to know? Int J Surg. 2020;82S:87-92. PMID 32305529
  24. Maspero M, et al. Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues. Cancers (Basel). 2023;15(2). PMID 36672295
  25. Simoneau E, D'Angelica M, Halazun KJ. Liver transplantation for colorectal liver metastasis. Curr Opin Organ Transplant. 2019;24(2):175-181. PMID 30839338
  26. Su L, et al. Thermal ablation versus liver resection for small colorectal liver metastases (≤3 cm): a systematic review and meta-analysis of randomized and propensity score-matched studies. Surg Endosc. 2026. PMID 42463528